02/12/2026
Vistagen today reported financial results for its fiscal year 2026 third quarter ended December 31, 2025, and provided a corporate update. The PALISADE-4 Phase 3 trial of fasedienol for acute treatment of Social Anxiety Disorder is proceeding, with topline results from the randomized portion of the trial expected in the first half of 2026. See Vistagen's corporate update here: https://bit.ly/3OEBeY5